Drug Profile
AUP 16
Alternative Names: AUP-16; AUP1602-CLatest Information Update: 20 Mar 2024
Price :
$50
*
At a glance
- Originator Aurealis Pharma
- Developer Aurealis Therapeutics
- Class Anti-inflammatories; Bacteria; Probiotics
- Mechanism of Action Bacteria replacements; Colony stimulating factor stimulants; Fibroblast growth factor stimulants; Interleukin 4 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Diabetic foot ulcer
- Phase I Varicose ulcer
- Preclinical Pressure ulcer
Most Recent Events
- 11 Mar 2024 AUP 16 receives Priority Medicine (PRIME) status for Diabetic foot ulcer in Europe
- 21 Jul 2023 Phase-II clinical trials in Diabetic foot ulcer in Poland, Italy, and Germany (Topical)
- 09 May 2023 Aurealis Therapeutics receives CTA approval for a phase II trial in Diabetic foot ulcer in Italy, Germany, and Poland